{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-014154","form_type":"8-K","ticker":"INM","cik":"0001728328","company_name":"InMed Pharmaceuticals Inc.","filed_at":"2025-02-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.641082+00:00","generated_at":"2026-05-26T21:28:10.287869+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"InMed reports Q2 net loss $2.6M, cash $3.5M; board accepts director resignation","bullets":["Net loss of $2.6M for Q2 FY2025 (Dec 31, 2024), vs $1.5M loss a year ago; GAAP loss per share $3.64.","Cash and equivalents $3.5M as of Dec 31, 2024; company raised $2.9M in Jan 2025, enough through Q2 2025.","BayMedica revenue $1.1M (-10% YoY); BayMedica achieved net income of $0.23M (189% improvement).","Board accepted resignation of director Janet Grove effective Feb 10, 2025, following withheld votes at Dec 2024 AGM.","R&D expenses $1M (up from $0.6M); pipeline updates: INM-901 (Alzheimer's) and INM-089 (dry AMD)."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-014154","json":"https://secwatch.observer/filing/0001213900-25-014154.json","markdown":"https://secwatch.observer/filing/0001213900-25-014154.md","text":"https://secwatch.observer/filing/0001213900-25-014154.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1728328/000121390025014154/0001213900-25-014154-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1728328/000121390025014154/ea0231142-8k_inmed.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T21:28:10.287869+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"24fb6427fb","claim":"Janet Grove resigned as Director at InMed Pharmaceuticals Inc..","evidence_excerpt":"On February 10, 2025, the Board elected to accept Ms. Grove’s resignation from the Board, including from her positions as a member of the Compensation Committee and Chair of the Nominating & Governance Committee.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1728328/000121390025014154/0001213900-25-014154-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}